31
Participants
Start Date
August 31, 2009
Primary Completion Date
October 31, 2012
Study Completion Date
October 31, 2012
Lenalidomide, Bortezomib
"Induction:~3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14~Consolidation (2 months After ASCT):~2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14~Maintenance Phase:~3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months"
Institut Paoli Calmette, Marseille
Centre François Baclesse, Caen
University Hospital of Dijon, Hôpital des Enfants, Dijon
University Hospital of Toulouse, Purpan, Toulouse
"University Hospital of Bordeaux, Hôpital du Haut Lévêque ", Pessac
Hôpital Bretonneau, Tours, Tours
University Hospital of Grenoble, Hôpital A.Michallon, BP 217 X, Grenoble
Hôpitaux de Brabois Nancy, Vandœuvre-lès-Nancy
University Hospital Of Lille, Hôpital Claude Huriez, Lille
Collaborators (1)
Celgene Corporation
INDUSTRY
Janssen-Cilag Ltd.
INDUSTRY
University Hospital, Toulouse
OTHER